This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Ad Hoc Group for the Study of Pertussis Vaccines.: Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet, 1, 955–960 (1988)Ad Hoc Group for the Study of Pertussis VaccinesPlacebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse eventsLancet1955960198810.1016/S0140-6736(88)91778-3Search in Google Scholar
Agnolon V., Bruno C., Leuzzi R., Galletti B., D’Oro U., Pizza M., Seubert A., O’Hagan D., Baudner B.: The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A. Int. J. Pharm. 492, 169–176 (2015)AgnolonV.BrunoC.LeuzziR.GallettiB.D’OroU.PizzaM.SeubertA.O’HaganD.BaudnerB.The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid AInt. J. Pharm.492169176201510.1016/j.ijpharm.2015.06.03026149936Search in Google Scholar
Alvarez Hayes J., Erben E., Lamberti Y., Principi G., Maschi F, Ayala M, Rodriguez M.: Bordetella pertussis iron regulated proteins as potential vaccine components. Vaccine, 31, 3543–3548 (2013)Alvarez HayesJ.ErbenE.LambertiY.PrincipiG.MaschiFAyalaMRodriguezM.Bordetella pertussis iron regulated proteins as potential vaccine componentsVaccine3135433548201310.1016/j.vaccine.2013.05.07223731630Search in Google Scholar
Asokanathan C., Corbel M., Xing D.: A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis. Hum. Vaccin. Immunother. 9, 325–331 (2013)AsokanathanC.CorbelM.XingD.A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussisHum. Vaccin. Immunother.9325331201310.4161/hv.22755385975523291942Search in Google Scholar
Bernard N, Finlay C Tannahill G, Cassidy J, O’Neill L, Mills K.: A critical role for the TLR signaling adapter Mal in alveolar macrophage-mediated protection against Bordetella pertussis. Mucosal Immunol. 8, 982–992 (2015)BernardNFinlayCTannahillGCassidyJO’NeillLMillsK.A critical role for the TLR signaling adapter Mal in alveolar macrophage-mediated protection against Bordetella pertussisMucosal Immunol.8982992201510.1038/mi.2014.12525515629Search in Google Scholar
Bodilis H., Guiso N.: Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg. Infect. Dis. 19, 471–474 (2013)BodilisH.GuisoN.Virulence of pertactin-negative Bordetella pertussis isolates from infants, FranceEmerg. Infect. Dis.19471474201310.3201/eid1903.121475Search in Google Scholar
Bottero D., Hozbor D. i wsp.: Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin. Vaccine Immunol. 14, 1490–1498 (2007)BotteroD.HozborD.i wsp.Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strainsClin. Vaccine Immunol.1414901498200710.1128/CVI.00177-07216817817699837Search in Google Scholar
Bottero D., Hozbor D. i wsp.: Characterization of the immune response induced by pertussis OMVs-based vaccine. Vaccine, 34, 3303–3309 (2016)BotteroD.HozborD.i wsp.Characterization of the immune response induced by pertussis OMVs-based vaccineVaccine3433033309201610.1016/j.vaccine.2016.04.07927151884Search in Google Scholar
Bouchez V., Hegerle N., Strati F., Njamkepo E., Guiso N.: New data on vaccine antigen deficient Bordetella pertussis isolates. Vaccines, 3, 751–770 (2015)BouchezV.HegerleN.StratiF.NjamkepoE.GuisoN.New data on vaccine antigen deficient Bordetella pertussis isolatesVaccines3751770201510.3390/vaccines3030751458647626389958Search in Google Scholar
Broder K., Cortese M., Iskander J.: Advisory Committee on Immunization Practices (ACIP) Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55, 1–34 (2006)BroderK.CorteseM.IskanderJ.Advisory Committee on Immunization Practices (ACIP) Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR Recomm. Rep.551342006Search in Google Scholar
Carbonetti N.: Bordetella pertussis: new concepts in pathogenesis and treatment. Curr. Opin. Infect. Dis. 29, 287–294 (2016)CarbonettiN.Bordetella pertussis: new concepts in pathogenesis and treatmentCurr. Opin. Infect. Dis.29287294201610.1097/QCO.0000000000000264484649226906206Search in Google Scholar
Cassiday P., Sanden G., Heuvelman K., Mooi F., Bisgard K., Popovic T.: Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935– 1999. J. Infect. Dis. 182, 1402–1408 (2000)CassidayP.SandenG.HeuvelmanK.MooiF.BisgardK.PopovicT.Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935– 1999J. Infect. Dis.18214021408200010.1086/315881Search in Google Scholar
Centers for Disease Control and Prevention.: Pertussis-United States, January 1992-June 1995. MMWR Morb. Mortal. Wkly. Rep. 44, 525–529 (1995)Centers for Disease Control and PreventionPertussis-United States, January 1992-June 1995MMWR Morb. Mortal. Wkly. Rep.445255291995Search in Google Scholar
Cherry J.: The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr. Probl. Pediatr. 14, 1–78 (1984)CherryJ.The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative studyCurr. Probl. Pediatr.14178198410.1016/0045-9380(84)90016-1Search in Google Scholar
Cherry J.: Epidemic pertussis and acellular pertussis vaccine failure in the 21st century. Pediatrics, 135, 1130–1132 (2015)CherryJ.Epidemic pertussis and acellular pertussis vaccine failure in the 21st centuryPediatrics13511301132201510.1542/peds.2014-411825941310Search in Google Scholar
Cherry J., Brunell P., Golden G.: Report of the task force on pertussis and pertussis immunization – 1988. Pediatrics, 81, 939–984 (1988)CherryJ.BrunellP.GoldenG.Report of the task force on pertussis and pertussis immunization – 1988Pediatrics81939984198810.1542/peds.81.6.933Search in Google Scholar
Cheung G., Xing D., Prior S., Corbel M., Parton R., Coote J.: Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model. Infect. Immun. 74, 6797–6805 (2006)CheungG.XingD.PriorS.CorbelM.PartonR.CooteJ.Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine modelInfect. Immun.7467976805200610.1128/IAI.01104-06169807516982827Search in Google Scholar
Cody C., Baraff L., Cherry J., Marcy S., Manclark C.: Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics, 68, 650–660 (1981)CodyC.BaraffL.CherryJ.MarcyS.ManclarkC.Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and childrenPediatrics68650660198110.1542/peds.68.5.650Search in Google Scholar
Cvjetanovic B., Grab B., Uemura K.: Diphtheria and whooping cough: diseases affecting a particular age group. Bull. World Health Organ. 56, 103–133 (1978)CvjetanovicB.GrabB.UemuraK.Diphtheria and whooping cough: diseases affecting a particular age groupBull. World Health Organ.561031331978Search in Google Scholar
de Gouw D., Serra D., de Jonge M., Hermans P., Wessels H., Zomer A., Yantorno O., Diavatopoulos D., Mooi F.: The vaccine potential of Bordetella pertussis biofilm-derived membrane proteins. Emerg. Microbes Infect. 3, e58 (2014)de GouwD.SerraD.de JongeM.HermansP.WesselsH.ZomerA.YantornoO.DiavatopoulosD.MooiF.The vaccine potential of Bordetella pertussis biofilm-derived membrane proteinsEmerg. Microbes Infect.3e58201410.1038/emi.2014.58415028626038752Search in Google Scholar
Diavatopoulos D., Edwards K.: What is wrong with Pertussis vaccine immunity? Why immunological memory to Pertussis is failing. Cold Spring Harb. Perspect Biol. 9, a029553 (2017)DiavatopoulosD.EdwardsK.What is wrong with Pertussis vaccine immunity? Why immunological memory to Pertussis is failingCold Spring Harb. Perspect Biol.9a029553201710.1101/cshperspect.a029553571010728289059Search in Google Scholar
Dunne A., Mielke L., Allen A., Sutton C., Higgs R., Cunningham C., Higgins S., Mills K.: A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine. Mucosal Immunol. 8, 607–617 (2015)DunneA.MielkeL.AllenA.SuttonC.HiggsR.CunninghamC.HigginsS.MillsK.A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccineMucosal Immunol.8607617201510.1038/mi.2014.9325315966Search in Google Scholar
Edwards K., Decker M., Halsey N., Koblin B., Townsend T., Auerbach B., Karzon D.: Differences in antibody response to whole-cell pertussis vaccines. Pediatrics, 88, 1019–1023 (1991)EdwardsK.DeckerM.HalseyN.KoblinB.TownsendT.AuerbachB.KarzonD.Differences in antibody response to whole-cell pertussis vaccinesPediatrics8810191023199110.1542/peds.88.5.1019Search in Google Scholar
Edwards K., Deloria M. i wsp.: Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics, 96, 548–557 (1995)EdwardsK.DeloriaM.i wsp.Comparison of 13 acellular pertussis vaccines: overview and serologic responsePediatrics96548557199510.1542/peds.96.3.548Search in Google Scholar
Fedele G., Bianco M., Ausiello C.: The virulence factors of Bordetella pertussis: talented modulators of host immune response. Arch. Immunol. Ther. Exp. 61, 445–457 (2013)FedeleG.BiancoM.AusielloC.The virulence factors of Bordetella pertussis: talented modulators of host immune responseArch. Immunol. Ther. Exp.61445457201310.1007/s00005-013-0242-1Search in Google Scholar
Fedele G., Bianco M., Debrie A., Locht C., Ausiello C.: Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J. Immunol. 186, 5388–5396 (2011)FedeleG.BiancoM.DebrieA.LochtC.AusielloC.Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 responseJ. Immunol.18653885396201110.4049/jimmunol.1003765Search in Google Scholar
Fernández S., Pérez J. i wsp.: A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models. BMC Immunol. 14, S8 (2013)FernándezS.PérezJ.i wsp.A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge modelsBMC Immunol.14S8201310.1186/1471-2172-14-S1-S8Search in Google Scholar
Feunou P., Ismaili J., Debrie A., Huot L., Hot D., Raze D., Lemoine Y., Locht C.: Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine, 26, 5722–5727 (2008)FeunouP.IsmailiJ.DebrieA.HuotL.HotD.RazeD.LemoineY.LochtC.Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1Vaccine2657225727200810.1016/j.vaccine.2008.08.018Search in Google Scholar
Fry N., Neal S., Harrison T., Miller E., Matthews R., George R.: Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect. Immun. 69, 5520–5528 (2001)FryN.NealS.HarrisonT.MillerE.MatthewsR.GeorgeR.Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United KingdomInfect. Immun.6955205528200110.1128/IAI.69.9.5520-5528.2001Search in Google Scholar
Gangarosa E., Galazka A., Wolfe C., Phillips L., Gangarosa R., Miller E., Chen R.: Impact of anti-vaccine movements on pertussis control: the untold story. Lancet, 351, 356–361 (1998)GangarosaE.GalazkaA.WolfeC.PhillipsL.GangarosaR.MillerE.ChenR.Impact of anti-vaccine movements on pertussis control: the untold storyLancet351356361199810.1016/S0140-6736(97)04334-1Search in Google Scholar
Garlapati S., Gerdts V. i wsp.: Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine, 29, 6540–6548 (2011)GarlapatiS.GerdtsV.i wsp.Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussisVaccine2965406548201110.1016/j.vaccine.2011.07.00921771625Search in Google Scholar
Gracia A., Polewicz M., Halperin S., Hancock R., Potter A., Babiuk L., Gerdts V.: Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine, 29, 1595–1604 (2011)GraciaA.PolewiczM.HalperinS.HancockR.PotterA.BabiukL.GerdtsV.Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulationsVaccine2915951604201110.1016/j.vaccine.2010.12.08321215343Search in Google Scholar
Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A., Anemona A.: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334, 341–348 (1996)GrecoD.SalmasoS.MastrantonioP.GiulianoM.TozziA.AnemonaA.A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working GroupN. Engl. J. Med.334341348199610.1056/NEJM1996020833406018538704Search in Google Scholar
Guiso N., Capiau C., Carletti G., Poolman J., Hauser P.: Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine, 17, 2366–2376 (1999)GuisoN.CapiauC.CarlettiG.PoolmanJ.HauserP.Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccinesVaccine1723662376199910.1016/S0264-410X(99)00037-7Search in Google Scholar
Guris D., Strebel P., Bardenheier B., Brennan M., Tachdjian R., Finch E., Wharton M., Livengood J.: Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clin. Infect. Dis. 28, 1230–1237 (1999)GurisD.StrebelP.BardenheierB.BrennanM.TachdjianR.FinchE.WhartonM.LivengoodJ.Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996Clin. Infect. Dis.2812301237199910.1086/51477610451158Search in Google Scholar
Gustafsson L., Hallander H. O., Olin P., Reizenstein E., Storsaeter J.: A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334, 349–355 (1996)GustafssonL.HallanderH. O.OlinP.ReizensteinE.StorsaeterJ.A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccineN. Engl. J. Med.334349355199610.1056/NEJM1996020833406028538705Search in Google Scholar
He Q., Mäkinen J., Berbers G., Mooi F., Viljanen M., Arvilommi H., Mertsola J.: Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J. Infec.t Dis. 187, 1200–1205 (2003)HeQ.MäkinenJ.BerbersG.MooiF.ViljanenM.ArvilommiH.MertsolaJ.Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants?J. Infec.t Dis.18712001205200310.1086/36841212695998Search in Google Scholar
He Q., Mertsola J.: Factors contributing to pertussis resurgence. Future Microbiol. 3, 329–339 (2008)HeQ.MertsolaJ.Factors contributing to pertussis resurgenceFuture Microbiol.3329339200810.2217/17460913.3.3.32918505398Search in Google Scholar
Hegerle N., Dore G., Guiso N.: Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine. Vaccine, 32 (2014)HegerleN.DoreG.GuisoN.Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccineVaccine32201410.1016/j.vaccine.2014.09.06825312274Search in Google Scholar
Hewlett E.: Pertussis: current concepts of pathogenesis and prevention. Pediatr. Infect. Dis. J. 16, 78–84 (1997)HewlettE.Pertussis: current concepts of pathogenesis and preventionPediatr. Infect. Dis. J.167884199710.1097/00006454-199704001-000029109161Search in Google Scholar
Hinman A., Koplan J.: Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs. JAMA, 251, 3109–3113 (1984)HinmanA.KoplanJ.Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costsJAMA25131093113198410.1001/jama.251.23.31096427489Search in Google Scholar
Howson C., Fineberg H.: Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of Medicine. JAMA, 267, 392–396 (1992)HowsonC.FinebergH.Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of MedicineJAMA267392396199210.1001/jama.267.3.392Search in Google Scholar
Jenkinson D.: Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Brit. Med. J. 296, 612–614 (1988)JenkinsonD.Duration of effectiveness of pertussis vaccine: evidence from a 10 year community studyBrit. Med. J.296612614198810.1136/bmj.296.6622.61225452433126927Search in Google Scholar
Jones A., Boucher P., Williams C, Stibitz S., Cotter P.: Role of BvgA phosphorylation and DNA binding affinity in control of Bvg-mediated phenotypic phase transition in Bordetella pertussis. Mol. Microbiol. 58, 700–713 (2005)JonesA.BoucherP.WilliamsCStibitzS.CotterP.Role of BvgA phosphorylation and DNA binding affinity in control of Bvg-mediated phenotypic phase transition in Bordetella pertussisMol. Microbiol.58700713200510.1111/j.1365-2958.2005.04875.x16238621Search in Google Scholar
Kammoun H., Feunou P., Foligne B., Debrie A., Raze D., Mielcarek N., Locht C.: Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice. Vaccine, 30, 5864–5870 (2012)KammounH.FeunouP.FoligneB.DebrieA.RazeD.MielcarekN.LochtC.Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in miceVaccine3058645870201210.1016/j.vaccine.2012.07.00522814407Search in Google Scholar
Kanai K.: Japan’s experience in pertussis epidemiology and vaccination in the past thirty years. Jpn. J. Med. Sci. Biol. 33, 107–143 (1980)KanaiK.Japan’s experience in pertussis epidemiology and vaccination in the past thirty yearsJpn. J. Med. Sci. Biol.33107143198010.7883/yoken1952.33.1077206322Search in Google Scholar
Kendrick P., Eldering G.: Progress report on pertussis immunization. Am. J. Public Health, 26, 8–12 (1936)KendrickP.ElderingG.Progress report on pertussis immunizationAm. J. Public Health26812193610.2105/AJPH.26.1.8156257118014359Search in Google Scholar
Kendrick P., Eldering G., Dixon M. K., Misner J.: Mouse protection tests in the study of pertussis vaccines: a comparative series using the intracerebral route of challenge. Am. J. Public Health, 37, 803–810 (1947)KendrickP.ElderingG.DixonM. K.MisnerJ.Mouse protection tests in the study of pertussis vaccines: a comparative series using the intracerebral route of challengeAm. J. Public Health37803810194710.2105/AJPH.37.7.803-bSearch in Google Scholar
King A., Berbers G., van Oirschot H., Hoogerhout P., Knipping K., Mooi F.: Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology, 147, 2885–2895 (2001)KingA.BerbersG.van OirschotH.HoogerhoutP.KnippingK.MooiF.Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunityMicrobiology14728852895200110.1099/00221287-147-11-288511700340Search in Google Scholar
Klein N.: Licensed pertussis vaccines in the United States. History and current state. Hum. Vacc. Immunother. 10, 2684–2690 (2014)KleinN.Licensed pertussis vaccines in the United States. History and current stateHum. Vacc. Immunother.1026842690201410.4161/hv.29576497506425483496Search in Google Scholar
Komatsu E., Yamaguchi F., Abe A., Weiss A., Watanabe M.: Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challange model. Clin. Vaccine Immunol. 17, 807–812 (2010)KomatsuE.YamaguchiF.AbeA.WeissA.WatanabeM.Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challange modelClin. Vaccine Immunol.17807812201010.1128/CVI.00449-09286339320357056Search in Google Scholar
Kostrzewski J., Magdzik W., Naruszewicz-Lesiuk D.: Choroby zakaźne i ich zwalczanie na ziemiach polskich w XX wieku. PZWL, Warszawa, 2001.KostrzewskiJ.MagdzikW.Naruszewicz-LesiukD.Choroby zakaźne i ich zwalczanie na ziemiach polskich w XX wiekuPZWLWarszawa2001Search in Google Scholar
Locht C., Mielcarek N. New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol. Med. Microbiol. 66, 121–133 (2012)LochtC.MielcarekN.New pertussis vaccination approaches: en route to protect newborns?FEMS Immunol. Med. Microbiol.66121133201210.1111/j.1574-695X.2012.00988.x22574832Search in Google Scholar
Locht C., Papin J., Lecher S., Debrie A., Thalen M., Solovay K., Rubin K., Mielcarek N.: Live Attenuated pertussis vaccine BPZE1 protects baboons against Bordetella pertussis disease and infection. J. Infect. Dis. 216, 117–124 (2017)LochtC.PapinJ.LecherS.DebrieA.ThalenM.SolovayK.RubinK.MielcarekN.Live Attenuated pertussis vaccine BPZE1 protects baboons against Bordetella pertussis disease and infectionJ. Infect. Dis.216117124201710.1093/infdis/jix254585337128535276Search in Google Scholar
Madsen T.: Vaccination against whooping cough. JAMA, 101, 187–188 (1933)MadsenT.Vaccination against whooping coughJAMA101187188193310.1001/jama.1933.02740280007003Search in Google Scholar
Mattoo S., Cherry J.: Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18, 326–382 (2005)MattooS.CherryJ.Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspeciesClin. Microbiol. Rev.18326382200510.1128/CMR.18.2.326-382.2005108280015831828Search in Google Scholar
Meldunki o zachorowaniach na choroby zakaźne, zakażeniach i zatruciach w Polsce, NIZP-PZH. Strona http://wwwold.pzh.gov.pl/oldpage/epimeld/index_p.html (10.08.2019).Meldunki o zachorowaniach na choroby zakaźne, zakażeniach i zatruciach w Polsce, NIZP-PZHStrona http://wwwold.pzh.gov.pl/oldpage/epimeld/index_p.html (10.08.2019)Search in Google Scholar
Melvin J., Scheller E., Miller J., Cotter P.: Bordetella pertussis pathogenesis: current and future challenges. Nat. Rev. Microbiol. 12, 274–288 (2014)MelvinJ.SchellerE.MillerJ.CotterP.Bordetella pertussis pathogenesis: current and future challengesNat. Rev. Microbiol.12274288201410.1038/nrmicro3235420556524608338Search in Google Scholar
Merkel T., Stibitz S., Keith J., Leef M., Shahin R.: Contribution of regulation by the bvg locus to respiratory infection of mice by Bordetella pertussis. Infect. Immun. 66, 4367–4373 (1998)MerkelT.StibitzS.KeithJ.LeefM.ShahinR.Contribution of regulation by the bvg locus to respiratory infection of mice by Bordetella pertussisInfect. Immun.6643674373199810.1128/IAI.66.9.4367-4373.19981085279712789Search in Google Scholar
Mielcarek N., Debrie A., Mahieux S., Locht C.: Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin.Vaccine Immunol. 17, 317–324 (2010)MielcarekN.DebrieA.MahieuxS.LochtC.Dose response of attenuated Bordetella pertussis BPZE1-induced protection in miceClin.Vaccine Immunol.17317324201010.1128/CVI.00322-09283796020107007Search in Google Scholar
Mielcarek N., Locht C. i wsp.: Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2, e65 (2006)MielcarekN.LochtC.i wsp.Live attenuated B. pertussis as a single-dose nasal vaccine against whooping coughPLoS Pathog.2e65200610.1371/journal.ppat.0020065148717516839199Search in Google Scholar
Miller D., Alderslade R., Ross E.: Whooping cough and whooping cough vaccine: the risks and benefits debate. Epidemiol. Rev. 4, 1–24 (1982)MillerD.AldersladeR.RossE.Whooping cough and whooping cough vaccine: the risks and benefits debateEpidemiol. Rev.4124198210.1093/oxfordjournals.epirev.a0362426128242Search in Google Scholar
Miyaji Y., Otsuka N., Toyoizumi-Ajisaka H., Shibayama K., Kamachi K.: Genetic analysis of Bordetella pertussis isolates from the 2008–2010 pertussis epidemic in Japan. PLoS One, 8, e77165 (2013)MiyajiY.OtsukaN.Toyoizumi-AjisakaH.ShibayamaK.KamachiK.Genetic analysis of Bordetella pertussis isolates from the 2008–2010 pertussis epidemic in JapanPLoS One8e77165201310.1371/journal.pone.0077165379074724124606Search in Google Scholar
Mooi F.: Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect. Genet. Evol. 10, 36–49 (2010)MooiF.Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogenInfect. Genet. Evol.103649201010.1016/j.meegid.2009.10.00719879977Search in Google Scholar
Mooi F., Van Der Maas N., De Melker H.: Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol. Infect. 142, 685–694 (2014)MooiF.Van Der MaasN.De MelkerH.Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coinEpidemiol. Infect.142685694201410.1017/S095026881300007123406868Search in Google Scholar
Mooi F., Mertsola J. i wsp.: Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg. Infect. Dis. 15, 1206–1213 (2009)MooiF.MertsolaJ.i wsp.Bordetella pertussis strains with increased toxin production associated with pertussis resurgenceEmerg. Infect. Dis.1512061213200910.3201/eid1508.081511Search in Google Scholar
Mooi F., van Oirschot H., Heuvelman K., van der Heide H., Gaastra W., Willems R.: Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66, 670–675 (1998)MooiF.van OirschotH.HeuvelmanK.van der HeideH.GaastraW.WillemsR.Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolutionInfect. Immun.66670675199810.1128/IAI.66.2.670-675.1998Search in Google Scholar
Mortimer E., Jones P.: An evaluation of pertussis vaccine. Rev. Infect. Dis. 1, 927–934 (1979)MortimerE.JonesP.An evaluation of pertussis vaccineRev. Infect. Dis.1927934197910.1093/clinids/1.6.927Search in Google Scholar
Mosiej E., Augustynowicz E., Zawadka M., Dąbrowski W., Lutyńska A.: Strain variation among Bordetella pertussis isolates circulating in Poland after 50 years of whole-cell pertussis vaccine use. J. Clin. Microbiol. 49, 1452e7 (2011)MosiejE.AugustynowiczE.ZawadkaM.DąbrowskiW.LutyńskaA.Strain variation among Bordetella pertussis isolates circulating in Poland after 50 years of whole-cell pertussis vaccine useJ. Clin. Microbiol.491452e7201110.1128/JCM.01487-10Search in Google Scholar
Mosiej E., Zawadka M., Krysztopa-Grzybowska K., Polak M., Augustynowicz E., Piekarska K., Lutynska A.: Sequence variation in virulence-related genes of Bordetella pertussis isolates from Poland in the period 1959–2013. Eur. J. Clin. Microbiol. Infect. Dis. 34, 147e52 (2015)MosiejE.ZawadkaM.Krysztopa-GrzybowskaK.PolakM.AugustynowiczE.PiekarskaK.LutynskaA.Sequence variation in virulence-related genes of Bordetella pertussis isolates from Poland in the period 1959–2013Eur. J. Clin. Microbiol. Infect. Dis.34147e52201510.1007/s10096-014-2216-6Search in Google Scholar
Ntezayabo B., De Serres G., Duval B.: Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr. Infect. Dis. J. 22, 22–27 (2003)NtezayaboB.De SerresG.DuvalB.Pertussis resurgence in Canada largely caused by a cohort effectPediatr. Infect. Dis. J.222227200310.1097/00006454-200301000-00009Search in Google Scholar
Olin P., Gustafsson L., Barreto L., Hessel L., Mast T., Rie A., Bogaerts H., Storsaeter J.: Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine, 21, 2015–2021 (2003)OlinP.GustafssonL.BarretoL.HesselL.MastT.RieA.BogaertsH.StorsaeterJ.Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccineVaccine2120152021200310.1016/S0264-410X(02)00777-6Search in Google Scholar
Onorato I., Wassilak S., Meade B.: Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA, 267, 2745–2749 (1992)OnoratoI.WassilakS.MeadeB.Efficacy of whole-cell pertussis vaccine in preschool children in the United StatesJAMA26727452749199210.1001/jama.1992.03480200053023Search in Google Scholar
Packard E., Parton R., Coote J., Fry N.: Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J. Med. Microbiol. 53, 355–365 (2004)PackardE.PartonR.CooteJ.FryN.Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UKJ. Med. Microbiol.53355365200410.1099/jmm.0.05515-015096543Search in Google Scholar
Plotkin S., Orenstein W., Offit P., Edwards K.: Plotkin’s Vaccines 7th Edition. Elsevier, 2017PlotkinS.OrensteinW.OffitP.EdwardsK.Plotkin’s Vaccines 7th EditionElsevier2017Search in Google Scholar
Polak M., Zasada A., Mosiej E., Krysztopa-Grzybowska K., Witkowski L., Rzeczkowska M., Piekarska K., Lutyńska A.: Pertactin-deficient Bordetella pertussis isolates in Poland – a country with whole-cell pertussis primary vaccination. Microbes Infect. 21, 170–175 (2018)PolakM.ZasadaA.MosiejE.Krysztopa-GrzybowskaK.WitkowskiL.RzeczkowskaM.PiekarskaK.LutyńskaA.Pertactin-deficient Bordetella pertussis isolates in Poland – a country with whole-cell pertussis primary vaccinationMicrobes Infect.21170175201810.1016/j.micinf.2018.12.00130580013Search in Google Scholar
Polewicz M., Gracia A., Buchanan R., Strom S., Halperin S., Potter A., Babiuk L., Gerdts V.: Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and piglets. Vaccine, 29, 7718–7726 (2011)PolewiczM.GraciaA.BuchananR.StromS.HalperinS.PotterA.BabiukL.GerdtsV.Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and pigletsVaccine2977187726201110.1016/j.vaccine.2011.07.135Search in Google Scholar
Ramsay M., Farrington C., Miller E.: Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol. Infect. 111, 41–48 (1993)RamsayM.FarringtonC.MillerE.Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periodsEpidemiol. Infect.1114148199310.1017/S095026880005665XSearch in Google Scholar
Roberts R., Moreno G., Bottero D., Gaillard M., Fingermann M., Graieb A., Rumbo M., Hozbor D.: Outer membrane vesicles as acellular vaccine against pertussis. Vaccine, 26, 4639–4646 (2008)RobertsR.MorenoG.BotteroD.GaillardM.FingermannM.GraiebA.RumboM.HozborD.Outer membrane vesicles as acellular vaccine against pertussisVaccine2646394646200810.1016/j.vaccine.2008.07.004Search in Google Scholar
Romanus V., Jonsell R., Bergquist S.: Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr. Infect. Dis. J., 6, 364–371 (1987)RomanusV.JonsellR.BergquistS.Pertussis in Sweden after the cessation of general immunization in 1979Pediatr. Infect. Dis. J.6364371198710.1097/00006454-198704000-00005Search in Google Scholar
Rumbo M., Hozbor D.: Development of improved pertussis vaccine. Hum. Vaccin. Immunother. 10, 2450–2453 (2014)RumboM.HozborD.Development of improved pertussis vaccineHum. Vaccin. Immunother.1024502453201410.4161/hv.29253Search in Google Scholar
Sato Y, Kimura M, Fukumi H.: Development of a pertussis component vaccine in Japan. Lancet, 1, 122–126 (1984)SatoYKimuraMFukumiH.Development of a pertussis component vaccine in JapanLancet1122126198410.1016/S0140-6736(84)90061-8Search in Google Scholar
Sato Y., Sato H.: Development of acellular pertussis vaccines. Biologicals, 27, 61–69 (1999)SatoY.SatoH.Development of acellular pertussis vaccinesBiologicals276169199910.1006/biol.1999.018110600185Search in Google Scholar
Seubert A., D’Oro U., Scarselli M., Pizza M.: Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines. Expert Rev. Vaccines, 13, 1191–1204 (2014)SeubertA.D’OroU.ScarselliM.PizzaM.Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccinesExpert Rev. Vaccines1311911204201410.1586/14760584.2014.94264125183193Search in Google Scholar
Shapiro-Shapin C.: Pearl Kendrick, Grace Eldering, and the pertussis vaccine. Emerg. Infect. Dis. 16, 1273–1278 (2010)Shapiro-ShapinC.Pearl Kendrick, Grace Eldering, and the pertussis vaccineEmerg. Infect. Dis.1612731278201010.3201/eid1608.100288329832520678322Search in Google Scholar
Sharma S., Benson H., Mukkur T., Rigby P., Chen Y.: Preliminary studies on the development of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasal delivery system for protein antigens. J. Microencapsul. 30, 283–294 (2013)SharmaS.BensonH.MukkurT.RigbyP.ChenY.Preliminary studies on the development of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasal delivery system for protein antigensJ. Microencapsul.30283294201310.3109/02652048.2012.72627922994538Search in Google Scholar
Shuel M., Jamieson F., Tang P., Brown S., Farrell D., Martin I., Stoltz J., Tsang R.: Genetic analysis of Bordetella pertussis in Ontario, Canada reveals one predominant clone. Int. J. Infect. Dis. 17, e413–417 (2013)ShuelM.JamiesonF.TangP.BrownS.FarrellD.MartinI.StoltzJ.TsangR.Genetic analysis of Bordetella pertussis in Ontario, Canada reveals one predominant cloneInt. J. Infect. Dis.17e413417201310.1016/j.ijid.2012.12.015Search in Google Scholar
Skerry C., Mahon B.: A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin. Vaccine Immunol. 18, 187–193 (2011)SkerryC.MahonB.A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine modelClin. Vaccine Immunol.18187193201110.1128/CVI.00371-10Search in Google Scholar
National Library of Medicine: First adult safety trial on nasal live attenuated B. pertussis vaccine 31.01.2012 https://clinicaltrials.gov/ct2/show/NCT01188512?cond=pertussis&draw=2&rank=7 (29.11.2019)National Library of Medicine: First adult safety trial on nasal live attenuated B. pertussis vaccine 31.01.2012https://clinicaltrials.gov/ct2/show/NCT01188512?cond=pertussis&draw=2&rank=7 (29.11.2019)Search in Google Scholar
Narodowy Instytut Zdrowia Publicznego – Państwowego Zakładu Higieny: Szczepienia-info, https://szczepienia.pzh.gov.pl/ (29.11.2019)Narodowy Instytut Zdrowia Publicznego – Państwowego Zakładu Higieny: Szczepienia-infohttps://szczepienia.pzh.gov.pl/ (29.11.2019)Search in Google Scholar
Thorstensson R., Locht C. i wsp.: A phase I clinical study of a live attenuated Bordetella pertussis vaccine – BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One, 9, e83449 (2014)ThorstenssonR.LochtC.i wsp.A phase I clinical study of a live attenuated Bordetella pertussis vaccine – BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteersPLoS One9e83449201410.1371/journal.pone.0083449Search in Google Scholar
Trollfors B. i Rabo E.: Whooping cough in adults. Brit. Med. J. 283, 696–697 (1981)TrollforsB. i RaboE.Whooping cough in adultsBrit. Med. J.283696697198110.1136/bmj.283.6293.696Search in Google Scholar
van Gent M., Pierard D., Lauwers S., van der Heide H.G., King A.J., Mooi F.R.: Characterization of Bordetella pertussis clinical isolates that do not express the tracheal colonization factor. FEMS Immunol. Med. Microbiol. 51, 149–154 (2007)van GentM.PierardD.LauwersS.van der HeideH.G.KingA.J.MooiF.R.Characterization of Bordetella pertussis clinical isolates that do not express the tracheal colonization factorFEMS Immunol. Med. Microbiol.51149154200710.1111/j.1574-695X.2007.00291.xSearch in Google Scholar
Weber C., Boursaux-Eude C., Coralie G., Caro V., Guiso N.: Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J. Clin. Microbiol. 39, 4396–4403 (2001)WeberC.Boursaux-EudeC.CoralieG.CaroV.GuisoN.Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 yearsJ. Clin. Microbiol.3943964403200110.1128/JCM.39.12.4396-4403.2001Search in Google Scholar
White J., Fairley C., Owen D., Matthews R., Miller E.: The effect of an accelerated immunisation schedule on pertussis in England and Wales. Commun. Dis. Rep. CDR Rev. 6, 86–91 (1996)WhiteJ.FairleyC.OwenD.MatthewsR.MillerE.The effect of an accelerated immunisation schedule on pertussis in England and WalesCommun. Dis. Rep. CDR Rev.686911996Search in Google Scholar
Williams M., Sen K., Weigand M., Skoff T., Cunningham V., Halse T., Tondella M.: CDC Pertussis Working Group. Bordetella pertussis strain lacking pertactin and pertussis toxin. Emerg. Infect. Dis. 22, 319–322 (2016)WilliamsM.SenK.WeigandM.SkoffT.CunninghamV.HalseT.TondellaM.CDC Pertussis Working Group. Bordetella pertussis strain lacking pertactin and pertussis toxinEmerg. Infect. Dis.22319322201610.3201/eid2202.151332Search in Google Scholar
Winter K., Zipprich J., Harriman K., Murray E., Gornbein J., Hammer S., Yeganeh N., Adachi K., Cherry J.: Risk factors associated with infant deaths from pertussis: a case-control study. Clin. Infect. Dis. 61, 1099–1106 (2015)WinterK.ZipprichJ.HarrimanK.MurrayE.GornbeinJ.HammerS.YeganehN.AdachiK.CherryJ.Risk factors associated with infant deaths from pertussis: a case-control studyClin. Infect. Dis.6110991106201510.1093/cid/civ472Search in Google Scholar
World Health Organization: Report of the meeting on case definition of pertussis, 10–11.01.1991, https://apps.who.int/iris/bitstream/handle/10665/66921/MIM_EPI_PERT_91.1.pdf?sequence=1&isAllowed=y (29.11.2019)World Health OrganizationReport of the meeting on case definition of pertussis, 10–11.01.1991https://apps.who.int/iris/bitstream/handle/10665/66921/MIM_EPI_PERT_91.1.pdf?sequence=1&isAllowed=y (29.11.2019)Search in Google Scholar
World Health Organization: Pertussis vaccines: WHO position paper. Weekly Epidemiological Record, 09.2015, https://www.who.int/wer/2015/wer9035.pdf?ua=1 (29.11.2019)World Health OrganizationPertussis vaccines: WHO position paperWeekly Epidemiological Record, 09.2015https://www.who.int/wer/2015/wer9035.pdf?ua=1 (29.11.2019)Search in Google Scholar
Zackrisson G., Taranger J., Trollfors B.: History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin. J. Pediatr. 116, 190–194 (1990)ZackrissonG.TarangerJ.TrollforsB.History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutininJ. Pediatr.116190194199010.1016/S0022-3476(05)82873-2Search in Google Scholar
